Poor systemic absorption has limited the, efficacy of early oral acyclovir in herpes zoster ophthalmic us (HZO).
open randomised study was performed to compare the ocular prophylactic effects of topical and oral acyclovir.
Fifty-seven patients with HZO within 72 hours of the onset of rash received either topical acyclovir ointment or 800 mg oral acyclovir, both 5 times daily for 7 days, and were followed for 12 months. Patients receiving ointment were significantly more likely to have ocular complica tions (p<0.02) and anterior uveitis was significantly more frequent (p<0.01) and severe (p<0.0l). Corneal hypo aesthesia was significantly more frequently (p<0.05) and severe (p<0.02) at 1 month. From 2 weeks patients receiv ing ointment were more likely to have pain and at all times their pain was more severe, but these differences wer� not statistically significant. In spite of its apparently better penetration topical acyclovir appears to have no prophylactic value in the management of early HZO.
Herpes zoster is the commonest disease of the nervous system. Prevalence increases with age and it has been esti mated that each individual has a 50% risk of being affected by age 85 years and a I % chance of being affected twice. 1 Of affected cases 10-17% are ophthalmic, and this is the second commonest site after thoracic dermatomes.1, 3 Ocular complications at some time after the onset of rash occur with a frequency of around 50% in herpes zoster Qphthalmicus (HZO), with activity persisting for 6 months or more in up to 28% of initially affected eyes. 4 Incidence and severity of ocular complications are not related to age, sex or severity of rash, but involvement of the external division of the nasociliary nerve is signifi cantly associated with the development of ocular compli cations. Complications in HZO are varied,4-R with anterior uveitis being the commonest followed by varieties of kera-titis. Onset of acute ocular complications ranges between 7 and 28 days. Up to 93% of patients with HZO experience acute pain.4 Chronic pain occurs in up to 34%,1,1,4,9,10 becoming more frequent with age and rising to 71 % in those aged 80 years and over. 4 Management of HZO remains controversial. Recent attention has centred on the role of antivirals and in par ticular acyclovir in management and prophylaxis. There is also a role for topical steroids but the precise relationship between these two therapeutic options remains unclear. 1 1, [ 1 Two studies have reported prophylactic effects in the eye of oral acyclovir in HZO provided it is commenced within 72 hours of the onset of rash.13.14 Results were somewhat conflicting, with one study show ing an early [ J and one a late effect. [4 A retrospective case control investigation failed to detect a significant thera peutic effect. [5 Double-masked placebo-controlled studies on the effect of acyclovir on pain in HZOU,14 and in non ophthalmic herpes zosterl6-18 have also produced con flicting results. All have shown a prophylactic effect on pain but this has either been early or late. Because of these studies the use of early oral acyclovir has become wide spread, although several ophthalmologists do not use oral acyclovir routinely for HZO because of the relatively high cost and doubts about efficacy.
Oral acyclovir is only partially absorbed, with plasma levels which plateau at doses above 800 mg[9 and are only slightly higher than the mean effective dose (EDs o ) for most strains of varicella zoster virus. 2 o , 2 1 It seems likely that the benefits of oral acyclovir are limited by poor systemic absorption. Aqueous humour levels are sub stantially higher if the drug is administered topically to the eye12 and this formulation may offer better ocular efficacy than the oral drug as well as being considerably cheaper. This paper reports on a multicentre randomised open study to compare the prophylactic effects of topical and oral acyclovir commenced early in the disease.
PATIENTS AND METHODS
Patients presenting with HZO with rash of less than 72 hours duration were recruited at three centres: St Paul's Eye Hospital, Liverpool; Manchester Royal Eye Hospital; and Royal Hallamshire Hospital, Sheffield. After giving their informed written consent patients were randomised at presentation to receive either topical acyclovir ointment 5 times daily for 7 days or 800 mg oral acyclovir 5 times daily for 7 days.
Ocular complications were defined as any ocular disease secondary to HZO but excluding mild surface ocular complications such as conjunctivitis and mild punctate keratopathy. Patients with established ocular complications at presentation were excluded. Other exclu sion criteria were: compromised immune status, topical or systemic antiviral therapy at presentation, pregnancy or lactation, renal failure, moderate or severe hypertension, diabetes mellitus, previous relevant eye disease including surgically treated cataract and glaucoma, chronic uveitis and keratitis.
Patients were assessed at the following intervals after commencement of treatment: 3-5 days (first half of treat ment), 7-10 days (second half of treatment), 2 weeks (immediate post-treatment), and 1,2,3,6 and 12 months. Additional visits were made as determined by the nature of any ocular complications.
Chronicity was defined as the presence of active ocular complications 6 months after the onset of rash when all ocular treatment had been withdrawn for a minimum of 2 weeks.
Variables measured were pain, anterior uveitis, sclero keratitis, scleritis, corneal involvement including disci form keratitis and corneal sensation. Severities were recorded on an ordinal scale from 0 to 3, with 0 repre senting absent. The highest score for flare, cells, keratic precipitates and hypopyon was taken as the total uveitis score for any particular visit. Corneal sensation was tested by comparison of a light touch with a cotton wool strand against the normal fellow eye and recorded as normal, reduced or absent. Pain was measured in response to the standard question, 'On average, how bad has the pain been in the last 24 hours?'; it was scored on a visual analogue scale set vertically for 100 mm. If ocular complications developed subsequently they were treated with topical acyclovir and steroids were with held except in severe or deteriorating disease (severe hypopyon uveitis, posterior scleritis, orbital apex syn drome).14 Cyclopentolate 1 % was used as necessary. Glau coma was controlled with topical beta-blockers (or dipivefrine in known asthmatics) if the intraocular pres sure rose above 30 mmHg. Post-herpetic pain was treated with sodium valproate and/or low-dose amitriptyline as necessary. Analgesics were stopped for 2 weeks at 6 months after the onset of rash to assess the frequency and severity of pain.
It was calculated that a sample size of 150 patients in each arm of the study would be required to detect a 50% difference in frequency of intraocular involvement with an 80% power based on an incidence of 30% with oral acy clovir.14 Study duration was estimated at 3 years on the basis of previous recruitment rates. Statistical analysis of frequencies was by one-tailed chi-squared (X2) test and of severities by the Mann-Whitney V-test (one-tailed).
RESULTS
Between March 1990 and May 1992, 70 patients with HZO were recruited within 72 hours of the onset of rash and commenced on treatment. During the early months recruitment rates were satisfactory but by 1992 the use of oral acyclovir in general practice had become so wide spread that the majority of patients presenting with HZO were already on treatment. Alternatively patients random ised to receive ointment were subsequently prescribed the oral drug by their general practitioner (GP) in spite of reg ular circular letters and discussion at postgraduate GP training sessions. In May 1992 further recruitment was abandoned at less than the planned sample size and fol low-up was completed.
Thirteen patients were excluded from final analysis: 9 were lost to follow-up within 6 weeks and in 4 patients in the ointment group oral acyclovir or steroids were added by other practitioners after recruitment. Data were avail able for analysis on 30 patients from Liverpool, 21 from Table   II . Throughout the follow-up period corneal sensation was more likely to be reduced or absent in patients receiving ointment and this was statistically significant at 1 month (p<0.05). Altered corneal sensation tended to recover between 1 and 3 months. Hypoaesthesia was more severe in the ointment group throughout follow-up and this difference was again significant at 1 month (p = 0.0 I). Frequencies and severity of pain during the time bands studied are shown in Tables III and IV . From 2 weeks patients receiving tablets were less likely to have pain than those receiving ointment and at all times during follow-up their pain was less severe. None of the differences were statistically significant.
DISCUSSION
Throughout the study there was a trend in favour of patients on oral drug developing less frequent and severe ocular complications. This was statistically significant at 3 and 12 months and also by cumulative analysis. In addi tion statistically significant benefits of tablets over oint ment were detected for anterior uveitis and loss of corneal sensation, for both frequency and severity.
Throughout the study there was a trend in favour of patients on oral drug having less frequent and severe zoster-associated pain. However, the final numbers avail able for data analysis give our results a statistical power that is lower than projected. Statistical significance was not reached for pain variables at any time; at 6 months the difference in pain severity scores gave a p value of 0.08
and so it is likely that given larger numbers this might have reached significance.
Frequencies of ocular complications in the oral treat ment group in our study were 34% overall and 8% at 6
months. These are similar to those found in patients stud ied previously in the north of England in which the inci dence of ocular complications was 30% overall and 5% at 6 months in patients treated with oral acyclovir.14 In this previous study the overall frequency of ocular complica tions was 53% in those receiving placebo. The frequency of ocular complications in the ointment group in our study (68%) was higher, and also higher than in previously pub lished work. It does not seem feasible that topical acyclo vir could enhance the subsequent development of ocular complications, but this high frequency strongly suggests that topical acyclovir offers no therapeutic advantages when given early. 
